Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Int Urol Nephrol. 2019 Dec;51(12):2235-2242. doi: 10.1007/s11255-019-02319-7. Epub 2019 Oct 22.
Hyperlipidemia and oxidative stress are indispensable features of chronic kidney disease (CKD) that favor the development of atherogenic plaques and cardiovascular disease (CVD). A number of vasoactive mediators including proprotein convertase subtilisin-kexin type 9 (PCSK9), endothelin-1, nitric oxide, and angiotensin II have fundamental roles in the pathophysiology of atherosclerotic events; moreover, their levels are affected by dyslipidemia and oxidative stress due to renal dysfunction. Therefore, therapeutic measures aimed at correcting dyslipidemia and alleviating oxidative stress could potentially protect against CVD in CKD patients. In this review, we discuss the relation between dyslipidemia, oxidative stress, and vasoactive mediators as well as the available treatment options against these disturbances in CKD patients.
高脂血症和氧化应激是慢性肾脏病（CKD）不可缺少的特征，有利于动脉粥样硬化斑块和心血管疾病（CVD）的发展。许多血管活性介质，包括前蛋白转化酶枯草溶菌素 9（PCSK9）、内皮素 1、一氧化氮和血管紧张素 II，在动脉粥样硬化事件的病理生理学中起着重要作用；此外，由于肾功能障碍，它们的水平受到血脂异常和氧化应激的影响。因此，旨在纠正血脂异常和减轻氧化应激的治疗措施可能有助于预防 CKD 患者的 CVD。在这篇综述中，我们讨论了血脂异常、氧化应激与血管活性介质之间的关系，以及针对 CKD 患者这些异常的现有治疗选择。
